Document Detail

The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics.
MedLine Citation:
PMID:  23139019     Owner:  NLM     Status:  MEDLINE    
While therapeutic proteins (TP), particularly recombinant human proteins and fully human monoclonal antibodies, are designed to have a low immunogenic potential in humans, a clinical immune response does sometimes occur and cannot be predicted from preclinical studies. Changes in TP pharmacokinetics may be perceived as an early indication of antibody formation and serve as a surrogate for later changes in efficacy and safety in individual subjects. Given the substantial increase in number of biological products, including biosimilars, there is an urgent need to quantitatively predict and quantify the immune response and any consequential changes in TP pharmacokinetics. The purpose of this communication is to review the utility of population-based modeling and simulation approaches developed to date for investigating the development of an immune response and assessing its impact on TP pharmacokinetics. Two examples of empirical modeling approaches for pharmacokinetic assessment are presented. The first example presents methods to analyze pharmacokinetic data in the presence of anti-drug antibody (ADA) and confirm the effect of immunogenicity on TP pharmacokinetics in early phases of drug development. The second example provides a framework to analyze pharmacokinetic data in the absence or with very low incidence of ADA and confirm with enough power the lack of an immunogenicity effect on TP pharmacokinetics in late phases of drug development. Finally, a theoretical mechanism-based modeling framework is presented to mathematically relate the complex interaction among TP, their targets, and ADA.
Juan Jose Perez Ruixo; Peiming Ma; Andrew T Chow
Related Documents :
24713439 - Proqm-resample: improved model quality assessment for membrane proteins by limited conf...
24887599 - Integration of eeg lead placement templates into traditional technologist-based staffin...
24551429 - Aslform: an adaptive self learning medical form generating system.
24462629 - Workshop report: strategies for setting occupational exposure limits for engineered nan...
23556979 - Robust detection of dynamic community structure in networks.
24690109 - Animal models for viral hemorrhagic fever.
10232629 - Four-component model of body composition in children: density and hydration of fat-free...
21335269 - A spatial agent-based model for the simulation of adults' daily walking within a city.
24365759 - A new access density definition and its correlation with crash rates by microscopic tra...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-11-10
Journal Detail:
Title:  The AAPS journal     Volume:  15     ISSN:  1550-7416     ISO Abbreviation:  AAPS J     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-03     Completed Date:  2013-08-02     Revised Date:  2013-11-14    
Medline Journal Info:
Nlm Unique ID:  101223209     Medline TA:  AAPS J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  172-82     Citation Subset:  IM    
Quantitative Pharmacology, Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / immunology*,  pharmacokinetics*
Computer Simulation
Models, Biological
Reg. No./Substance:
0/AMG 317; 0/Antibodies, Monoclonal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A pharmacokinetic simulation tool for inhaled corticosteroids.
Next Document:  Determination of the dominant arachidonic acid cytochrome p450 monooxygenases in rat heart, lung, ki...